nivolumab and hyaluronidase-nvhy (Opdivo Qvantig)
nivolumab and hyaluronidase-nvhy is an FDA-licensed reference biologic from Bristol-Myers Squibb Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2025
Reference approved
Reference product
Opdivo Qvantig nivolumab and hyaluronidase-nvhy
Bristol-Myers Squibb Company
- Approved
- Nov 24, 2025
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for nivolumab and hyaluronidase-nvhy, in chronological order.
Reference approval
Approval date of the reference nivolumab and hyaluronidase-nvhy product.
6 mo ago
Frequently asked questions
Are there biosimilars approved for nivolumab and hyaluronidase-nvhy (Opdivo Qvantig)?
No 351(k) biosimilars or interchangeable biosimilars referencing nivolumab and hyaluronidase-nvhy are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.